Stay updated on LAG-3 in GBM: Alone & with Nivolumab Clinical Trial
Sign up to get notified when there's something new on the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page.

Latest updates to the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThis update shows a minor revision update: Revision: v3.3.4 replacing v3.3.3, with no changes to study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedThe page now includes a consolidated Locations section listing study sites by state (Alabama, California, Maryland, Massachusetts, Michigan, New York, North Carolina, Ohio, Pennsylvania) and updates the revision to v3.3.3; the HHS Vulnerability Disclosure link was removed.SummaryDifference0.9%

- Check59 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.0%

- Check66 days agoChange DetectedRemoved the government funding/status notice from the page, while core study details remain unchanged.SummaryDifference0.3%

- Check80 days agoChange DetectedThere are no significant updates to core study information; observed differences appear to be minor formatting or layout adjustments only. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check108 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference2%

Stay in the know with updates to LAG-3 in GBM: Alone & with Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page.